Incyte Corporation (INCY)
Automate Your Wheel Strategy on INCY
With Tiblio's Option Bot, you can configure your own wheel strategy including INCY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INCY
- Rev/Share 24.5981
- Book/Share 23.7706
- PB 4.5868
- Debt/Equity 0.0089
- CurrentRatio 3.1938
- ROIC 0.2074
- MktCap 21405064308.0
- FreeCF/Share 6.1177
- PFCF 17.8816
- PE 17.949
- Debt/Assets 0.0065
- DivYield 0
- ROE 0.2983
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | INCY | H.C. Wainwright | -- | Buy | -- | $135 | Feb. 5, 2026 |
| Downgrade | INCY | Wells Fargo | Overweight | Equal Weight | -- | $107 | Jan. 20, 2026 |
| Upgrade | INCY | Mizuho | Neutral | Outperform | -- | $121 | Dec. 8, 2025 |
| Upgrade | INCY | Guggenheim | Neutral | Buy | -- | $125 | Nov. 3, 2025 |
| Downgrade | INCY | Oppenheimer | Outperform | Perform | -- | -- | Oct. 8, 2025 |
| Upgrade | INCY | Wells Fargo | Equal Weight | Overweight | -- | $89 | Aug. 6, 2025 |
| Initiation | INCY | Barclays | -- | Overweight | -- | $90 | Aug. 1, 2025 |
| Upgrade | INCY | Stifel | Hold | Buy | -- | $107 | June 16, 2025 |
| Downgrade | INCY | Guggenheim | Buy | Neutral | -- | -- | March 18, 2025 |
| Downgrade | INCY | William Blair | Outperform | Market Perform | -- | -- | March 18, 2025 |
News
Incyte Corporation (INCY) Q4 2025 Earnings Call Transcript
Published: February 10, 2026 by: Seeking Alpha
Sentiment: Neutral
Incyte Corporation (INCY) Q4 2025 Earnings Call Transcript
Read More
INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Neutral
Incyte posts a Q4 EPS miss but a 28% revenue jump, fueled by Jakafi and Opzelura strength, as product sales top estimates.
Read More
Incyte (INCY) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Incyte (INCY) Q4 Earnings Lag Estimates
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Negative
Incyte (INCY) came out with quarterly earnings of $1.8 per share, missing the Zacks Consensus Estimate of $1.94 per share. This compares to earnings of $1.43 per share a year ago.
Read More
Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.
Read More
Here's Why Incyte (INCY) is a Strong Value Stock
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards?
Published: February 06, 2026 by: Zacks Investment Research
Sentiment: Positive
INCY heads into Q4 earnings with strong Jakafi sales, rising royalties and multiple new launches contributing to revenues, setting the stage for a potential upside surprise.
Read More
Unveiling Incyte (INCY) Q4 Outlook: Wall Street Estimates for Key Metrics
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Incyte (INCY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
Published: January 30, 2026 by: Business Wire
Sentiment: Neutral
MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC).
Read More
Here's Why Incyte (INCY) is a Strong Momentum Stock
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why Incyte (INCY) is a Top Value Stock for the Long-Term
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Incyte: Buy For The Turnaround, Stay For The Pipeline
Published: January 16, 2026 by: Seeking Alpha
Sentiment: Positive
Incyte Corporation earns a Strong Buy rating, with recent execution driving a 56% stock rally and robust revenue growth. Jakafi sales rose 6.7% YoY in Q3 2025, defying terminal decline fears, while ex-Jakafi business surged 45% YoY. Management projects ex-Jakafi revenues to triple by 2030, with pipeline catalysts and Jakafi XR mitigating the 2028 patent cliff.
Read More
Steven Cress' Top 10 Stocks For 2026
Published: January 15, 2026 by: Seeking Alpha
Sentiment: Positive
Micron Technology (MU) leads Steven Cress' Top 10 Stocks for 2026, driven by sector-leading growth, profitability, and a compelling valuation despite a 254% 1-year return. AI remains a central investment theme, with hyperscalers like MU, AMD, and CIEN benefiting from robust CapEx, strong forward EPS growth, and discounted PEG ratios.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 12, 2026 by: Seeking Alpha
Sentiment: Neutral
Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report?
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins
Published: January 06, 2026 by: Seeking Alpha
Sentiment: Positive
Incyte Corporation remains a Buy, driven by robust Hem/Oncology portfolio growth and key Monjuvi/Minjuvi expansion catalysts. INCY's Hem/Onc portfolio revenues surged 107% YoY in Q3 2025, fueled by Monjuvi/Minjuvi and Niktimvo performance. Positive phase 3 frontMIND data for Monjuvi enables a 1st-line DLBCL sBLA filing in H1 2026, expanding addressable market.
Read More
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Neutral
Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.
Read More
Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer
Published: January 05, 2026 by: Benzinga
Sentiment: Positive
Incyte Corporation (NASDAQ: INCY) on Monday shared topline results from the pivotal Phase 3 frontMIND trial of tafasitamab (Monjuvi/Minjuvi) combo as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Read More
Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock?
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: December 22, 2025 by: Business Wire
Sentiment: Neutral
TOKYO--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma.
Read More
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
Published: December 22, 2025 by: Business Wire
Sentiment: Neutral
TOKYO--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer.
Read More
EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
INCY wins EC approval expanding Minjuvi's label, adding a new indication for relapsed or refractory follicular lymphoma after prior therapy.
Read More
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: December 17, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma.
Read More
Here's Why Incyte (INCY) is a Strong Value Stock
Published: December 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Calls of the Day: Netflix, Thermo Fisher, Incyte and Shake Shack
Published: December 09, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
About Incyte Corporation (INCY)
- IPO Date 1993-11-04
- Website https://www.incyte.com
- Industry Biotechnology
- CEO William Meury
- Employees 2617